Table 5.
RAM in Haematological Malignancies; Cohort and Performance
| RAM | Subtype | No | Performance |
|---|---|---|---|
| Leukaemia | |||
| KRS55 | AML | 867 AML | Suboptimal performance (P = 0.19) |
| ISTH-DIC8 | AML/APL | 272(adult)+ 132 (elderly) AML/63APL | Good performance, HR 4.79 (1.71–13.45)/ (P = 0.001). |
| AL Ani et al score | AML/APL/ALL | 501 | Good performance C-statistic of 0.664 (95% CI: 0.590–0.738) |
| Lymphoma | |||
| KRS31 | Multiple validation studies | Unable stratify low risk patients | |
| ThroLy score56,57 | All subtypes | 1820 (derivation)+428(validation) | Inadequate discrimination |
| Hohaus el al. score58 | All subtypes | 857 | Identified 82% of VTE but needs validation |
| TiC-Lympho59 | All subtypes | 254 | AUC 0.783; however, a feasibility trial needed |
| CATSCORE18 | All subtypes | 249 in derivation | Needs validation |
| Multiple myeloma (MM) | |||
| IMPEDE VTE60 score | MM | Derivation 4446 Validation 4256 |
Good performance outperformed the current IMWG/NCCN guidelines (p < 0.0001) |
| SAVED Score61 | MM | Derivation (2397) validation (1251) | Good performance (p < 0.01) |
| ROADMAP-CAT-MM score62 | MM | 144 | Good performance, Feasibility validation trial required |
| KRS60 | MM | 2874 | Poor prediction value c-statistic 0.52 |